Overview
This is a Phase 1 study carried out at a single site in 88 healthy male subjects and healthy female subjects of non childbearing potential to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DNL343.
Eligibility
Key Inclusion Criteria:
- Women of non-childbearing potential and men; aged 18-50 years, inclusive
- BMI 18-32 kg/m, inclusive, and body weight of at least 50 kg
Key Exclusion Criteria:
- History of clinically significant neurologic, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders